Tradestie Institutional Equity Comparison Engine
CGEM vs ENTA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEM Overall Edge
CGEM Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CGEM trades at 6.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ENTA at 44.0x Forward P/E and -90.0% operating margin (-21.6% YoY). In options structure, CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against ENTA sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEM
CGEM 6.7x vs ENTA 44.0x Fwd P/E
Growth & Margin Winner
CGEM
Op Margin 0.0% vs -90.0% ยท YoY +0.0% vs -21.6%
Momentum & Technical Winner
CGEM
1Y +14.9% vs -9.0% ยท 52W Pos 10% vs 9%
Options & Structure Winner
CGEM
UNCLASSIFIED (9th %ile IV) vs BREAKDOWN (11th %ile IV)
CGEM
NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.50
-7.59% 1D
Market Cap
$653.8M
1M Return
-26.53%
1Y Return
+14.87%
Forward P/E
6.7x
Unified AI Score
41.0 / 100
SELL
Tech 25.0
Fund 51.0
Flow 50.0
Mom 59.0
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.67
-2.91% 1D
Market Cap
$326.2M
1M Return
-3.87%
1Y Return
-8.96%
Forward P/E
44.0x
Unified AI Score
46.2 / 100
HOLD
Tech 53.0
Fund 54.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CGEM +14.87%
ENTA -8.96%
Spread: +23.83 pp (CGEM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CGEM TTM Op. Margin: 0.0%
ENTA TTM Op. Margin: -90.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs ENTA. Trailing 12-month operating profitability (CGEM 0.0% vs ENTA -90.0%) and valuation multiples (CGEM 6.7x vs ENTA 44.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGEM | ENTA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $653.8M | $326.2M | Larger Scale | CGEM |
| Trailing P/E Ratio Valuation | 6.7x | 44.0x | Lower Multiple | CGEM |
| Forward P/E Ratio Valuation | 6.7x | 44.0x | Lower Multiple | CGEM |
| Revenue Growth (YoY) Growth | +0.0% | -21.6% | Higher Growth | CGEM |
| Operating Margin (TTM) Profitability | 0.0% | -90.0% | Higher Margin | CGEM |
| Net Profit Margin Profitability | 0.0% | -96.9% | Higher Margin | CGEM |
| Return on Equity (ROE) Capital Efficiency | -50.3% | -70.1% | Higher ROE | CGEM |
| 52-Week Range Position Momentum | 10% ($8โ$23) | 9% ($10โ$17) | Stronger Trend | CGEM |
| Beta / 30D Volatility Risk Regime | 1.59ฮฒ ยท 105% Vol | 0.88ฮฒ ยท 58% Vol | Lower Realized Risk | ENTA |
| Unified Institutional Score Composite Signal | 41.0 / 100 (SELL) | 46.2 / 100 (HOLD) | Higher Composite | ENTA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CGEM vs ENTA Buy Guide
CGEM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
ENTA
BREAKDOWN
95d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CGEM nor ENTA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.